


NCI-NIH Integrative Medicine Course Organizing Committee



Registration

OMB No.: 0925-0740
Expiration Date: 07/31/2022

Public reporting burden for this collection of information is estimated to average 3 minutes per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing the collection of information. **An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB control number.** Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to: NIH, Project Clearance Branch, 6705 Rockledge Drive, MSC 7974, Bethesda, MD 20892-7974, ATTN: PRA (0925-0740). Do not return the completed form to this address.

Prefix

Mr., Ms., Mrs., Dr., Prof., etc.

First Name*

Last Name*

Email*

Position*

- Select -



Institution*

Select all upcoming seminars you would like to attend:

April 22 - 3:00-5:00 PM EST

3:00-4:00 PM EST - *Pellocybin at the End of Life*

Charles Grob, M.D. Professor of Psychiatry and Pediatrics, UCLA School of Medicine

4:00-5:00 PM EST - *Pellocybin: Neuropsychopharmacology and Implications for Therapeutics*

Roland Griffiths, Ph.D. Professor of Psychiatry and Behavioral Sciences, JHU School of Medicine

May 27 - 11:00 AM - 1:30 PM EST

11:00-12:00 PM EST - *Psychedelics - Science Policy Considerations and Perspective: Advancing Public Health through Dynamic Regulatory Frameworks*

Sean Belouin, Pharm.D. CAPT, United States Public Health Service, Senior Science Policy Advisor, SAMHSA

12:00-12:45 PM EST - *Transcendent, Spiritual, and Humane: Psychedelic Medicine Ends the Epoch of Psychiatric Reductionism and Rouses the Dawn of a New Mental Health Universe*

Erica Rex, MA. Journalist & Writer for *Scientific American* and *The New York Times*, National Magazine Award Winner.

12:45-1:30 PM EST - *Pellocybin in Cancer Patients with Depression—The Experience at Aquilino Cancer Center*

Manish Agrawal, M.D. Cancer center Director, Aquilino Cancer Center

June 4 - 1:00 PM - 3:15 PM EST

1:00-1:30 pm EST - *Self-blinding Citizen Science to Explore Psychedelic Microdosing*

Balázs Szigeti, PhD. Center for Psychedelic Research, Imperial College London

1:30-2:30 pm EST - *Pellocybin and Group Therapy: Implications for Safety and Efficacy*

Brian Anderson, M.D. MSC. Assistant Professor, Psychiatry, UCSF School of Medicine Alicia Danforth, Ph.D. Clinical Psychologist

2:30-3:15 pm EST - *Panel Discussion: Psychedelic Medicine and Ethics* Paul S. Appelbaum, MD. Dollard Professor of Psychiatry, Medicine, & Law, Columbia University College of Physicians & Surgeons

Mason Marks, MD, JD. Assistant Professor of Law, Gonzaga University

William Smith, MD, PhD, Psychiatry Resident, Perelman School of Medicine, University of Pennsylvania

June 7 - 2:00 PM - 3:30 PM EST

2:00-2:45 PM EST - *New Insights into the Mechanism of Action of Pellocybin*

Bryan Roth, M.D. Ph.D. MICHAEL HOOKER DISTINGUISHED PROFESSOR, UNC School of Medicine

2:45-3:30 PM EST - *Preliminary experimental systems to study antidepressant-like effects of pellocybin*

Charles Nichols, PhD. Professor, Department of Pharmacology and Experimental Therapeutics, LSU Health Sciences Center

June 10 - 1:00 PM - 2:30 PM EST

1:00-1:45 PM EST - *Pellocybin-Assisted Psychotherapy for Advanced Cancer-related Psychiatric and Existential Distress*

Stephen Ross, M.D. Associate Professor, Department of Psychiatry at NYU Grossman School of Medicine

1:45-2:30 PM EST - *Discussion*

TBD and NIH Staff

Submit